Gene: AZIN2

113451
ADC|AZI2|AZIB1|ODC-p|ODC1L|ODCp
antizyme inhibitor 2
protein-coding
1p35.1
Ensembl:ENSG00000142920 MIM:608353 Vega:OTTHUMG00000004130 UniprotKB:Q96A70
NC_000001.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.407e-1 (AD)  8.007e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs676069chr1:33156476 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00114Pyridoxal PhosphateSmall Molecule54-47-7Approved|Investigational|NutraceuticalTarget
DB00125L-ArginineSmall Molecule74-79-3Approved|NutraceuticalTarget
ID Drug Name Action PubMed
D000082AcetaminophenAcetaminophen results in increased expression of AZIN2 mRNA25704631|2906747
D020106AcrylamideAcrylamide results in increased expression of AZIN2 mRNA28959563
C006780bisphenol Abisphenol A results in increased expression of AZIN2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of AZIN2 gene28505145
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AZIN2 mRNA28628672
D019256Cadmium ChlorideCadmium Chloride results in increased expression of AZIN2 protein16372273
D019256Cadmium ChlorideCadmium Chloride results in decreased methylation of AZIN2 promoter22457795
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of AZIN2 mRNA23650126
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of AZIN2 mRNA20938992
C480342clothianidinclothianidin results in decreased expression of AZIN2 mRNA29044138
C014347decitabinedecitabine affects the expression of AZIN2 mRNA23300844
D003907DexamethasoneDexamethasone results in decreased expression of AZIN2 mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AZIN2 mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of AZIN2 mRNA17361019|2126653
D002945CisplatinCisplatin affects the expression of AZIN2 mRNA23300844
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of AZIN2 mRNA20938992
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AZIN2 mRNA28628672
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of AZIN2 mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AZIN2 mRNA28628672
C544151jinfukangjinfukang results in increased expression of AZIN2 mRNA27392435
C017461lead nitratelead nitrate results in decreased expression of AZIN2 mRNA21628963
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of AZIN2 mRNA20938992
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of AZIN2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of AZIN2 mRNA"25554681
D009966OrphenadrineOrphenadrine affects the expression of AZIN2 mRNA23665939
D011441PropylthiouracilPropylthiouracil results in decreased expression of AZIN2 mRNA24780913
C017947sodium arsenitesodium arsenite results in decreased expression of AZIN2 mRNA28595984
D012969Sodium FluorideSodium Fluoride results in decreased expression of AZIN2 mRNA21340527
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of AZIN2 mRNA26377647|2892240
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of AZIN2 mRNA25613284
D014212TretinoinTretinoin results in increased expression of AZIN2 mRNA23724009
C012589trichostatin Atrichostatin A affects the expression of AZIN2 mRNA28542535
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of AZIN2 mRNA"26179874
D014520UrethaneUrethane results in increased expression of AZIN2 mRNA28818685
D014635Valproic AcidValproic Acid results in increased expression of AZIN2 mRNA29154799
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of AZIN2 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004586ornithine decarboxylase activity-IBA21873635  
GO:0004586ornithine decarboxylase activityNOTIBA21873635  
GO:0005515protein binding-IPI17900240  25416956  
GO:0008792arginine decarboxylase activity-TAS-  
GO:0015489putrescine transmembrane transporter activity-ISS-  
GO:0042978ornithine decarboxylase activator activity-IBA21873635  
GO:0042978ornithine decarboxylase activator activity-IDA17900240  
GO:0042978ornithine decarboxylase activator activity-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007283spermatogenesis-NAS11587527  
GO:0015847putrescine transport-ISS-  
GO:0033387putrescine biosynthetic process from ornithine-IBA21873635  
GO:0042177negative regulation of protein catabolic process-IDA17900240  
GO:0042177negative regulation of protein catabolic process-ISS-  
GO:0043085positive regulation of catalytic activity-IBA21873635  
GO:0043085positive regulation of catalytic activity-ISS-  
GO:0097055agmatine biosynthetic process-TAS-  
GO:0098629trans-Golgi network membrane organization-IMP20188728  
GO:1902269positive regulation of polyamine transmembrane transport-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA19718454  19832840  
GO:0005737cytoplasm-IBA21873635  
GO:0005739mitochondrion-IEA-  
GO:0005801cis-Golgi network-ISS-  
GO:0005802trans-Golgi network-IDA20188728  
GO:0005829cytosol-TAS-  
GO:0030133transport vesicle-IMP20188728  
GO:0030424axon-IDA19832840  
GO:0030425dendrite-IDA19832840  
GO:0031410cytoplasmic vesicle-IDA19832840  20188728  
GO:0033116endoplasmic reticulum-Golgi intermediate compartment membrane-ISS-  
GO:0043204perikaryon-IDA19832840  
GO:0048471perinuclear region of cytoplasm-IDA20188728  
GO:1990005granular vesicle-IDA19718454  
KEGG ID KEGG Term
hsa00330Arginine and proline metabolism
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-351143Agmatine biosynthesisTAS
R-HSA-351202Metabolism of polyaminesTAS
R-HSA-71291Metabolism of amino acids and derivativesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal